| |
Nintedanib (n = 39)
|
Pirfenidone (n = 51)
|
p-value
|
|---|
|
Age, years
|
70 (7)
|
72 (7)
|
0.22
|
|
Male sex – no. (%)
|
35 (90)
|
47 (92)
|
0.72
|
|
FVC % predicted
|
86 (16)
|
76 (16)
|
0.01
|
|
FVC (L)
|
3.4 (0.9)
|
2.9 (0.6)
|
0.01
|
|
DLCO % predicted
|
48 (14)
|
49 (14)
|
0.69
|
|
K-BILD total score
|
56.5 (9)
|
56.7 (10)
|
0.89
|
|
EQ 5D-Index value
|
0.78 (0.15)
|
0.77 (0.19)
|
0.78
|
|
EQ5D-VAS scale
|
65 (24)
|
63 (23)
|
0.66
|
|
VAS – cough*
|
4.8 (2.6)
|
4.6 (2.5)
|
0.66
|
|
VAS – dyspnea*
|
5.1 (2.3)
|
5.6 (2.4)
|
0.43
|
|
VAS – general complaints**
|
5.6 (2.4)
|
5.5 (2.4)
|
0.75
|
|
HADS – depression score
|
3.0 (3.1)
|
3.9 (3.5)
|
0.21
|
|
HADS – anxiety score
|
4.7 (2.3)
|
4.6 (2.3)
|
0.94
|
- Data are presented as mean (SD). FVC forced vital capacity, DLCO diffusion capacity of the lung for carbon monoxide, K-BILD King’s Brief Interstitial Lung Disease questionnaire, VAS visual analogue scale, HADS Hospital Anxiety and Depression Scale. * a higher score represent worse symptoms, ** a higher score represents fewer symptoms
